H. Lundbeck A/S
๐ฉ๐ฐDenmark
- Country
- ๐ฉ๐ฐDenmark
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 5.6K
- Market Cap
- -
- Website
- http://www.lundbeck.com
Efficacy of Nalmefene in Patients With Alcohol Dependence
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 598
- Registration Number
- NCT00811720
- Locations
- ๐ฆ๐น
AT004, Salzburg, Austria
๐ซ๐ฎFI008, Helsinki, Finland
๐ฉ๐ชDE006, Hamburg, Germany
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 665
- Registration Number
- NCT00811941
- Locations
- ๐บ๐ฆ
UA010, Ternopil, Ukraine
๐จ๐ฟCZ001, Usti nad Labem, Czech Republic
๐ต๐ฑPL011, Krakow, Poland
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 453
- Registration Number
- NCT00811252
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 124
- Registration Number
- NCT00810667
- Locations
- ๐ต๐ฑ
PL012, Lodz, Poland
๐ต๐ฑPL009, Belchatow, Poland
๐ง๐ชBE001, Liege, Belgium
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 490
- Registration Number
- NCT00807248
- Locations
- ๐ท๐บ
RU011, Yaroslavl, Russian Federation
๐ท๐บRU014, Volgograd, Russian Federation
๐ท๐บRU015, Moscow, Russian Federation
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 492
- Registration Number
- NCT00790920
- Locations
- ๐ฆ๐บ
AU006, Clayton, Australia
๐ซ๐ทFR012, Limoges, France
๐ฎ๐ณIN008, Hyderabad, India
Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 459
- Registration Number
- NCT00788034
- Locations
- ๐ท๐บ
RU001, Tomsk, Russian Federation
๐ฟ๐ฆZA012, Cape Town, South Africa
๐ฟ๐ฆZA010, Cape Town, South Africa
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 105
- Registration Number
- NCT00771134
- Locations
- ๐บ๐ธ
US024, Atlanta, Georgia, United States
Efficacy of Lu 31-130 in Patients With Schizophrenia
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 93
- Registration Number
- NCT00770744
- Locations
- ๐จ๐ฟ
CZ004, Lnare, Czech Republic
๐จ๐ฟCZ002, Olomouc, Czech Republic
๐ซ๐ทFR002, Dole, France
Efficacy of Lu 31-130 in Patients With Schizophrenia
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 280
- Registration Number
- NCT00768326
- Locations
- ๐ฉ๐ช
DE001, Munich, Germany
ยฉ Copyright 2024. All Rights Reserved by MedPath